Loading
Life sciences · Journal article
Jac-antimicrobial Resistance · November 2, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Objectives. Aminoglycosides are often combined with β-lactams for the treatment of carbapenem-resistant Enterobacterales, but the impact of aminoglycoside-modifying enzyme (AME) genes on treatment efficacy in phenotypically susceptible isolates remains unclear. We evaluated whether aac(6')-Ib-cr, the AME gene with recognized activity against amikacin, attenuates amikacin efficacy in KPC-producing Klebsiella pneumoniae.Methods. Thirteen clinical isolates of KPC-producing K. pneumoniae without phenotypic aminoglycoside resistance (amikacin MIC ≤4 mg/L; median 2, range 0.5-3 mg/L) were studied. Three were AME-negative; 10 were AME-positive, carrying aac(6')-Ib-cr, aac(3)-IIa and strA/strB. Amikacin activity was assessed by time-kill assays and a Galleria mellonella survival model, compared with ceftazidime-avibactam.Results. In time-kill assays, amikacin killing at 24 h was greater in AME-negative isolates than in AME-positive isolates (mean 4.28 ± 1.30 versus 2.41 ± 2.16 log10 cfu/mL), with more regrowth by 72 h in AME-positive isolates (median 1.94 [0-5.82] versus 0 [0-3.32] log10). In the survival model, amikacin reduced larval mortality versus saline (HR, 0.32; 95% CI, 0.24-0.43; P < 0.001). The interaction between AME-positive status and amikacin (HR, 2.11; 95% CI, 1.54-2.90; P < 0.001) indicated reduced efficacy that persisted after adjustment for amikacin MIC (adjusted HR, 2.09; 95% CI, 1.52-2.86; P < 0.001). Ceftazidime-avibactam reduced mortality (HR, 0.24; 95% CI, 0.18-0.33; P < 0.001) with no significant interaction with AME gene status (HR, 1.03; 95% CI, 0.71-1.48; P = 0.894).Conclusion. Carriage of aac(6')-Ib-cr was associated with reduced amikacin efficacy despite phenotypic susceptibility, independently of amikacin MIC, consistent with a treatment effect modifier rather than a binary resistance determinant. Genotyping of aac(6')-Ib-cr may help guide aminoglycoside use in carbapenem-resistant Klebsiella pneumoniae infections.